Ignyta, Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|
| Revenue | — | — | $150,000 | — | — |
| Operating income | −$100.7M | −$90.6M | −$39.9M | −$13.9M | −$1.3M |
| Net income | −$25.5M | −$23.5M | −$40.0M | −$14.2M | −$1.3M |
| Total assets | $144.9M | $195.5M | $85.3M | $53.3M | $5.4M |
| Total liabilities | $50.1M | $59.5M | $29.4M | $11.5M | $882,877 |
| Equity | $94.8M | $136.0M | $55.9M | $41.8M | $4.6M |
| EPS (diluted) | — | — | — | $0.00 | $0.00 |
| Shares out. | 32.3M | 32.3M | 19.6M | 8.7M | 653,334 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- —
- Net margin
- —
- Return on equity
- −26.9%
- Return on assets
- −17.6%
- Return on capital (ROCE)
- −79.0%
- Liabilities / assets
- 34.6%
- Debt / equity
- 0.53×
- Book value / share
- $2.93
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Altman Z″ (distress)
- -4.08distress
- Accruals / assets
- 44.6%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Start Valerie Denise HardingOfficer — SVP, Chemistry, Mfg & Controls | Feb 8, 2018 | D | 29,188 | $27.00 |
| Multani Pratik SOfficer — Chief Medical Officer | Feb 8, 2018 | D | 74,134 | $27.00 |
| Mccarthy William ROfficer — Chief Business Officer | Feb 8, 2018 | D | 22,199 | $27.00 |
| Lim Jonathan EOfficer — President, CEO & Director | Feb 8, 2018 | D | 179,661 | $27.00 |
| Kuhlen Christian VOfficer — General Counsel and Secretary | Feb 8, 2018 | D | 22,019 | $27.00 |
| Hornby ZacharyOfficer — Chief Operating Officer | Feb 8, 2018 | D | 165,748 | $27.00 |
| Freddo James LDirector | Feb 8, 2018 | D | 3,000 | $27.00 |
| Chacko JacobOfficer — Chief Financial Officer | Feb 8, 2018 | D | 70,572 | $27.00 |
| Casdin Alexander W.Director | Feb 8, 2018 | D | 706,464 | $27.00 |
| Bristol James ADirector | Feb 8, 2018 | D | 21,845 | $27.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventFeb 8, 2018
- Director / officer changeDec 28, 2017
- Entered a material agreement · Regulation FD disclosureDec 22, 2017
- Results of operationsNov 7, 2017
- Other material eventOct 20, 2017
- Regulation FD disclosure · Other material eventOct 18, 2017
- Regulation FD disclosure · Other material eventOct 17, 2017
- Regulation FD disclosure · Other material eventSep 11, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- EFFECTFeb 22, 2018
- EFFECTFeb 22, 2018
- EFFECTFeb 22, 2018
- EFFECTFeb 22, 2018
- 15-12BFeb 20, 2018
- SC 13G/AAMENDMENT NO. 1Feb 15, 2018
- SC 13G/AAMENDMENT NO. 1Feb 14, 2018
- SC 13G/AFeb 14, 2018
- SC 13G/AFeb 14, 2018
- SC 13G/AFeb 13, 2018
- POS AMPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3Feb 12, 2018
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 12, 2018
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 12, 2018
- POS AMPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3Feb 12, 2018
- S-8 POSFeb 12, 2018
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.